Immobilized biologically active entities having a high degree of biological activity following sterilization

• US 8,496,953 B2
• Filed: 05/12/2006
• Issued: 07/30/2013
• Est. Priority Date: 05/12/2006
• Status: Active Grant

• Current Assignee: W. L. Gore & Associates (W.L. Gore & Associates)
• Original Assignee: W. L. Gore & Associates (W.L. Gore & Associates)
• Inventors: Cleek, Robert L., Daly, Michael D., Pietrzak, Krzysztof R.
• Primary Examiner(s): Wax, Robert A
• Assistant Examiner(s): Tcherkasskaya, Olga V
• Application Number:
  US11/433,105
• Publication Number:
  US 20070264301A1
• Time in Patent Office: 2,636 Days
• Field of Search: None
• US Class Current: 424/423
• CPC Class Codes: A61L 2/206 Ethylene oxide
• CPC Class Codes: A61L 33/0011 Anticoagulant, e.g. heparin, platelet aggregation inhibitor, fibrinolytic agent, other than enzymes, attached to the substrate

Abstract

The present invention is directed to immobilized biologically active entities that retain significant biological activity following sterilization of the immobilized biologically active entities.

Claims

1. A sterilized medical device comprising:

a fluoropolymeric substrate material;

a polymeric covering material comprising imine groups that is attached to at least a portion of a surface of said substrate material, a plurality of biologically active entities having anti-thrombin III binding activity covalently attached to at least a portion of said polymeric covering material, wherein said plurality of biologically active entities comprises polysaccharides; and

a biologically compatible organic composition non-covalently combined with said biologically active entities,

wherein said biologically compatible organic composition comprises a carbohydrate,

wherein said biologically active entities have an anti-thrombin III binding activity of at least 5 picomoles anti-thrombin III per square centimeter (pmol/cm²) substrate material following ethylene oxide sterilization of said biologically active entities.

2. The sterilized medical device of claim 1 wherein said plurality of biologically active entities comprises a glycosaminoglycan.

3. The sterilized medical device of claim 1 wherein said plurality of biologically active entities comprises end-point attached heparin.

4. The sterilized medical device of claim 1 wherein at least a portion of said biologically compatible organic composition is released from said sterilized medical device in a 0.15M phosphate buffer solution having a temperature of about thirty-seven degrees centigrade and a substantially neutral pH.

5. The sterilized medical device of claim 1 wherein said biologically compatible organic composition is a polysaccharide.

6. The sterilized medical device of claim 5 wherein said polysaccharide comprises a glycosaminoglycan.

7. The sterilized medical device of claim 6 wherein said glycosaminoglycan is heparin.

8. The sterilized medical device of claim 5 wherein said polysaccharide is dextran.

9. The sterilized medical device of claim 5 wherein said polysaccharide is dextran sulfate.

10. The sterilized medical device of claim 1 wherein said plurality of biologically active entities have an anti-thrombin III binding activity of at least 6 picomoles anti-thrombin III per square centimeter (pmol/cm²) substrate material following sterilization of said biologically active entities.

11. The sterilized medical device of claim 10 wherein said plurality of biologically active entities comprises a glycosaminoglycan.

12. The sterilized medical device of claim 10 wherein said plurality of biologically active entities comprises end-point attached heparin.

13. The sterilized medical device of claim 10 wherein at least a portion of said biologically compatible organic composition is released from said sterilized medical device in a 0.15M phosphate buffer solution having a temperature of about thirty-seven degrees centigrade and a substantially neutral pH.

14. The sterilized medical device of claim 1 wherein said plurality of biologically active entities have an anti-thrombin III binding activity of at least 7 picomoles anti-thrombin III per square centimeter (pmol/cm²) substrate material following sterilization of said biologically active entities.

15. The sterilized medical device of claim 14 wherein said plurality of biologically active entities comprises a glycosaminoglycan.

16. The sterilized medical device of claim 14 wherein said plurality of biologically active entities comprises end-point attached heparin.

17. The sterilized medical device of claim 14 wherein at least a portion of said biologically compatible organic composition is released from said sterilized medical device in a 0.15M phosphate buffer solution having a temperature of about thirty-seven degrees centigrade and a substantially neutral pH.

18. The sterilized medical device of claim 1 wherein said plurality of biologically active entities have an anti-thrombin III binding activity of at least 8 picomoles anti-thrombin III per square centimeter (pmol/cm²) substrate material following sterilization of said biologically active entities.

19. The sterilized medical device of claim 18 wherein said plurality of biologically active entities comprises a glycosaminoglycan.

20. The sterilized medical device of claim 18 wherein said plurality of biologically active entities comprises end-point attached heparin.

21. The sterilized medical device of claim 18 wherein at least a portion of said biologically compatible organic composition is released from said sterilized medical device in a 0.15M phosphate buffer solution having a temperature of about thirty-seven degrees centigrade and a substantially neutral pH.

22. The sterilized medical device of claim 1 wherein said plurality of biologically active entities have an anti-thrombin III binding activity of at least 9 picomoles anti-thrombin III per square centimeter (pmol/cm²) substrate material following sterilization of said biologically active entities.

23. The sterilized medical device of claim 22 wherein said plurality of biologically active entities comprises a glycosaminoglycan.

24. The sterilized medical device of claim 22 wherein said plurality of biologically active entities comprises end-point attached heparin.

25. The sterilized medical device of claim 22 wherein at least a portion of said biologically compatible organic composition is released from said sterilized medical device in a 0.15M phosphate buffer solution having a temperature of about thirty-seven degrees centigrade and a substantially neutral pH.

26. The sterilized medical device of claim 1 wherein said plurality of biologically active entities have an anti-thrombin III binding activity of at least 10 picomoles anti-thrombin III per square centimeter (pmol/cm²) substrate material following sterilization of said biologically active entities.

27. The sterilized medical device of claim 26 wherein said plurality of biologically active entities comprises a glycosaminoglycan.

28. The sterilized medical device of claim 26 wherein said plurality of biologically active entities comprises end-point attached heparin.

29. The sterilized medical device of claim 26 wherein at least a portion of said biologically compatible organic composition is released from said sterilized medical device in a 0.15M phosphate buffer solution having a temperature of about thirty-seven degrees centigrade and a substantially neutral pH.

30. The sterilized medical device of claim 1 wherein said polymeric covering material comprises multiple layers, wherein chemical components of at least one layer are cross-linked.

31. The sterilized medical device of claim 1 wherein said fluoropolymeric material is polytetrafluoroethylene.

32. The sterilized medical device of claim 1 wherein said polymeric covering material comprises at least one layer of polyethylene imine.

33. A sterilized medical device comprising:

a fluoropolymeric substrate material;

a polymeric covering material comprising imine groups that is attached to at least a portion of a surface of said substrate material;

a first plurality of heparin molecules having anti-thrombin III binding activity end point attached to at least a portion of said polymeric covering material; and

a biologically compatible organic composition non-covalently combined with said first plurality of heparin molecules,

wherein said biologically compatible organic composition comprises a carbohydrate,

wherein said first plurality of heparin molecules have an anti-thrombin III binding activity of at least 10 picomoles anti-thrombin III per square centimeter (pmol/cm²) substrate material following ethylene oxide sterlization of said first plurality of heparin molecules.

34. The sterilized medical device of claim 33 wherein at least a portion of said biologically compatible organic composition is released from said sterilized medical device in a 0.15M phosphate buffer solution having a temperature of about thirty-seven degrees centigrade and a substantially neutral pH.

35. The sterilized medical device of claim 33 wherein said biologically compatible organic composition is a polysaccharide.

36. The sterilized medical device of claim 35 wherein said polysaccharide comprises a glycosaminoglycan.

37. The sterilized medical device of claim 35 wherein said polysaccharide is an anticoagulation agent.

38. The sterilized medical device of claim 37 wherein said anticoagulation agent is heparin.

39. The sterilized medical device of claim 35 wherein said polysaccharide is dextran.

40. The sterilized medical device of claim 35 wherein said polysaccharide is dextran sulfate.

41. The sterilized medical device of claim 33 wherein said polymeric covering material comprises at least one layer of polyethylene imine.

42. The sterilized medical device of claim 33 wherein said polymeric covering material comprises multiple layers, wherein chemical components of at least one layer are cross-linked.

43. The sterilized medical device of claim 33 wherein said fluoropolymeric material is polytetrafluoroethylene.

44. The sterilized medical device of claim 33 wherein said polymeric covering material comprises at least one layer of polyethylene imine.

45. A sterilized medical device comprising:

a fluoropolymeric substrate material;

a polymeric covering material comprising imine groups that is attached to at least a portion of a surface of said substrate material;

a first plurality of heparin molecules having anti-thrombin III binding activity end point attached to at least a portion of said polymeric covering material; and

a composition comprising a second plurality of heparin molecules non-covalently combined with said first plurality of heparin molecules;

wherein said first plurality of heparin molecules have an anti-thrombin III binding activity of at least 10 picomoles anti-thrombin III per square centimeter (pmol/cm²) substrate material following ethylene oxide sterilization of said first plurality of heparin molecules.

46. The sterilized medical device of claim 45 wherein at least a portion of said second plurality of heparin molecules is released from said sterilized medical device in a 0.15M phosphate buffer solution having a temperature of about thirty-seven degrees centigrade and a substantially neutral pH.

47. The sterilized medical device of claim 45 wherein said polymeric covering material comprises multiple layers, wherein chemical components of at least one layer are cross-linked.

48. The sterilized medical device of claim 45 wherein said fluoropolymeric material is polytetrafluoroethylene.

49. The sterilized medical device of claim 45 wherein said polymeric covering material comprises at least one layer of polyethylene imine.

50. A sterilized medical device comprising:

a fluoropolymeric substrate material;

a polymeric covering material comprising imine groups that is attached to at least a portion of a surface of said substrate material;

a first plurality of heparin molecules having anti-thrombin III binding activity end point attached to at least a portion of said polymeric covering material; and

a composition comprising a second plurality of heparin molecules non-covalently combined with said first plurality of heparin molecules,

wherein said first plurality of heparin molecules have an anti-thrombin III binding activity of at least 100 picomoles anti-thrombin III per square centimeter (pmol/cm²) substrate material following ethylene oxide sterilization of said first plurality of heparin molecules.

51. The sterilized medical device of claim 50 wherein at least a portion of said second plurality of heparin molecules is released from said sterilized medical device in a 0.15M phosphate buffer solution having a temperature of about thirty-seven degrees centigrade and a substantially neutral pH.

52. The sterilized medical device of claim 50 wherein said polymeric covering material comprises multiple layers, wherein chemical components of at least one layer are cross-linked.

53. The sterilized medical device of claim 50 wherein said fluoropolymeric material is polytetrafluoroethylene.

54. The sterilized medical device of claim 50 wherein said polymeric covering material comprises at least one layer of polyethylene imine.